Monitoring lymphoma treatment with pet scans and blood tests
Treatments studied
Part of Cancer clinical trials.
This study tests whether using PET scans and a simple blood test (called liquid biopsy) can quickly and accurately monitor how well your lymphoma is responding to standard first-line treatment. The goal is to see if these real-time monitoring tools can improve care for aggressive B-cell lymphomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a specific type of fast-growing B-cell lymphoma (like diffuse large B-cell lymphoma) or a slow-growing lymphoma that has turned fast-growing
- You have not yet had any chemotherapy or other cancer drugs for this current lymphoma
- You can speak and understand French
- Your PET scan before treatment shows at least one measurable area of lymphoma (a lymph node bigger than 1.5 cm or a spot outside the lymph nodes bigger than 1 cm)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a treatment approach guided by PET scans, plus non-invasive monitoring, for adults with limited-stage diffuse large B-cell lymphoma (a type of lymphoma). It may help by tailoring therapy based on scan and other follow-up information, aiming for better outcomes with fewer invasive steps.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial looks at whether PET/CT scans can better predict outcomes in people with fast-growing lymphoma. If you are newly diagnosed and receiving standard treatment, the study may help refine how response is evaluated.
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
Hear when a new Aggressive B-cell Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.